CA2142142A1 - Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract - Google Patents
Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tractInfo
- Publication number
- CA2142142A1 CA2142142A1 CA002142142A CA2142142A CA2142142A1 CA 2142142 A1 CA2142142 A1 CA 2142142A1 CA 002142142 A CA002142142 A CA 002142142A CA 2142142 A CA2142142 A CA 2142142A CA 2142142 A1 CA2142142 A1 CA 2142142A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- press
- active ingredient
- medicinal active
- coated layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
Abstract
A pharmaceutical preparation for oral administration comprising (a) a core containing a medicinal active ingredient, (b) a press-coated layer comprising a pH-independently water-soluble polymer, said layer being provided around the core and (c) a film comprising an enteric polymer, said film being provided around the press-coated layer. In the pharmaceutical preparation of the present invention, the medicinal active ingredient is not released during residence in the stomach and, after forwarded from the stomach, until reaching a targeted site in the intestine, and thereafter is quickly released, so that the medicinal active ingredient is efficiently delivered to the targeted site in the intestinal tract.
Description
PHARMACEUTICAL PREPARATION CONTROLLED TO RELEASE
MEDICINAL ACTIVE INGREDIENT AT TARGETED SITE IN
INTESTINAL TRACT
BACKGROUND OF THE INVENTION
The present invention relates to a pharmaceutical preparation controlled to release a medicinal active ingredient at a targeted site in the 5 gastrointestinal tract, and more particularly to a pharmaceutical preparation for oral ~(lministration from which a medicinal active ingredient can be selectively delivered to any specific site in the intestinal tract.
Selective delivery of a medicinal active 10 ingredient to a specific site in the intestinal tract has been desired in drug therapies, for instance, a local therapy for inflammatory disease in the intestinal tract such as ulcerative colitis or Crohn s disease, or an oral ~1ministrative therapy with a medicinal compound of a 15 peptide which is apt to be decomposed chemically or enzymatically in the intestinal tract, with a medicinal compound of which the absorption site is limited, or with other medicinal compound.
In order to efficiently realize the selective 20 delivery of a medicinal active ingredient to a specific site in the intestinal tract, it is necessary to design a pharmaceutical preparation taking into account the physical and physiological environment in the human gastrointestinal tract and the traveling time of the 25 pharmaceutical preparation in the intestinal tract. With respect to the physical and physiological environment in the gastrointestinal tract, it is recognized that the value of pH in the stomach is usually 1. 8 to 4. 5 in a healthy human and that the value of pH in the intestines 3 0 is 6 . 5 to 7. 5 and the pH does not essentially differ between the small intestine and the large intestine.
According to the results of the widespread research of Davis et al., the residence time of a pharmaceutical preparation in the human stomach is 0.5 to 10 hours and further not only the inter-individual variation thereof is large, but also the residence time is considerably influenced, for example, by feeding, a size of the pharmaceutical preparation to be ~rlministered and the 5 like. However, the traveling time of a pharmaceutical preparation through the small intestine is generally recognized to be 3+1 hours and the inter- and intra-individual variation is relatively small (Journal of Controlled Release, 2, 27-38 (1985)).
With respect to a method by which a medicinal active ingredient can be selectively delivered to a specific site in the intestinal tract, hitherto various researches have been done. There have been proposed a pharmaceutical preparation wherein a sustained release 15 pharmaceutical preparation is coated with an enteric coating (Annals of the New York Ac~-lemy of Science, 618, 428-440 (1991)), a pharmaceutical preparation obtained by utilizing a technique for controlling the starting time of the release (Chemical & Pharmaceutical Bulletin, 40, 20 3036-3041 (1992)) and the like, as well as pharmaceutical preparations obtained by using known techniques such as an enteric pharmaceutical preparation and a sustained release pharmaceutical preparation.
However, every conventional method has a problem 25 such as insufficient site-selectivity or poor practicality due to peculiarity of the material to be used. For example, in case of using the enteric pharmaceutical preparation, the release of a medicinal active ingredient starts abruptly at the upper small intestine resulting in 30 consumption of almost of the medicinal active ingredient by absorption or decomposition before the medicinal active ingredient reaches the targeted site in the intestine, although the release of the medicinal active ingredient can be effectively suppressed in the stomach. In case of 35 using the sustained release pharmaceutical preparation, a considerable amount of a medicinal active ingredient is released when the pharmaceutical preparation stays in the stomach and passes through the small intestine because the _ -- 3 medicinal active ingredient is continuously released.
Further, in order to release a medicinal active ingredient at the large intestine, there has been recently developed a system utilizing the ecosystem of specific microorganisms in the large intestine. For example, in a pharmaceutical preparation wherein a composition containing a medicinal active ingredient is coated with a novel polymer having an azo group, or the composition cont~ining a medicinal active ingredient is dispersed in the new polymer having an azo group to form a matrix type of pharmaceutical preparation (Science, 233, 1081-1084 ( 1986)), the polymer is decomposed in the large intestine by enterobacteria having azo-reductase activity and the medicinal active ingredient is thereby released at the large intestine. However, for practical use, there are still many problems to be solved, for example, regarding the safety of the polymer itself, the controllability of the decomposition rate thereof, and the like.
An object of the present invention is to solve the above-mentioned problems in the conventional pharmaceutical preparations, and to provide a pharmaceutical preparation for oral ~rlministration by which a medicinal active ingredient can be effectively 25 released at a targeted site in the intestinal tract.
This and the other objects of the present invention will become apparent from the description hereinafter.
SUMl\~ARY OF THE INVENTION
In accordance with the present invention, there is provided a pharmaceutical preparation for oral ~lministration comprising (a) a core cont~ining a medicinal active ingredient, 3 5 (b) a press-coated layer comprising a pH-independently water-soluble polymer, said layer being provided around the core and (c) a film comprising an enteric polymer, said film being 21421~2 provided around the press-coated layer.
The pharmaceutical preparation of the present invention has the following characteristics: when the pharmaceutical preparation is orally ~rlmini~tered, the 5 release of a medicinal active ingredient does not occur at all during residence of the pharmaceutical preparation in the stomach and, after discharge from the stomach, until the preparation reaches a desirable targeted site in the intestine and thereafter, the release of the ingredient 10 starts rapidly. In case of using a medicinal active ingredient as a drug required to be selectively delivered to a specific site in the intestinal tract, an excellent pharmaceutical preparation having high av~ bility can be provided.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graph showing the result of the dissolution test with the first fluid and the second fluid of the dissolution test in Japanese Pharmacopoeia XII
20 (hereinafter referred to as JPXII) using a pharmaceutical preparation in Example 1.
Fig. 2 is a graph showing the result of the dissolution test with the second fluid of the dissolution test in JPXII using a pharmaceutical preparation after 25 immersing in the first fluid of the dissolution test in JPXII for a certain time in Experimental Example 1.
Fig. 3 is a graph showing the result of the dissolution test with the second fluid of the dissolution test in JPXII using three kinds of pharmaceutical 30 preparations having different coating amounts of the press-coated layer in Experimental Example 2.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a pharmaceutical 35 preparation from which a medicinal active ingredient can be selectively released at a targeted site in the intestinal tract, by comhining an enteric polymer, which dissolves dependent on a value of pH, and a press-coated 21~21~2 layer comprising a pH-independently water-soluble polymer.
In the pharmaceutical preparation of the present invention, the concrete structure thereof can be suitably selected so that a medicinal active ingredient can be 5 released at the desirable targeted site in the intestinal tract.
In the pharmaceutical preparation of the present invention, the functions of the film (c) comprising an enteric polymer are to prevent the penetration of water 10 during residence of the pharmaceutical preparation in the stomach so that the contents [ core (a) and press-coated layer (b)] thereof can be protected, and to quickly dissolve according as the surrounding pH increases after discharge of the pharmaceutical preparation from the 15 stomach so that the contents are forwarded to the upper small intestine. The press-coated layer (b) perfectly prevents the penetration of water into the core (a), unless the press-coated layer (b) dissolves, and therefore the press-coated layer (b) suppresses the release of 20 the medicinal active ingredient in the intestine after discharge of the pharmaceutical preparation from the stomach. Namely, the press-coated layer (bj is capable of suppressing the release of the medicinal active ingredient in the intestine until the pharmaceutical preparation 25 reaches near the desirable targeted site.
In order to sufficiently exhibit the above-mentioned capacity in the pharmaceutical preparation of the present invention, it is desirable to determine the coating amount of the film (c) so that the pharmaceutical 30 preparation has sufficient acid resistance and the film (c) prevents the penetration of water into the pharmaceutical preparation during residence in the stomach. It is also desirable to determine the time required for dissolution of the press-coated layer (b) 35 in the intestine so that the press-coated layer (b) can substantially suppress the release of the medicinal active ingredient until the pharmaceutical preparation re~ches near the desirable targeted site in the intestine.
21421~2 From the above-mentioned viewpoints, it is desirable that the coating amount of the film (c) is usually determined so that the film (c) prevents the penetration of water during residence in the stomach for a 5 period of about 10 hours which is recognized as the m~ximum residence time of a pharmaceutical preparation in the stomach, and that in case of targeting the upper large intestine, the coating amount of the press-coated layer (b) is determined so that the press-coated layer (b) can 10 suppress the release of a medicinal active ingredient in the intestines for about 3+1 hours which is recognized as a general traveling time of a pharmaceutical preparation through the small intestine.
The pharmaceutical preparation of the present 15 invention can be suitably designed so that when a dissolution test is carried out according to the dissolution test (puddle method; 37C; 100 rpm; 900 mQ of dissolution fluid) of JPXII (refer to Example 1), release of a medicinal active ingredient is substantially 20 suppressed for at least 10 hours in the first fluid (pH 1. 2), and the release of the medicinal active ingredient is substantially suppressed for at least about 2 hours in the second fluid (pH 6.8) and thereafter the release of the medicinal active ingredient starts quickly.
25 The time required to start the release of the medicinal active ingredient (hereinafter referred to as alag-time" ) in the second fluid is set to meet the desired target-site in the intestinal tract. For example, in case that the pharmaceutical preparation of the present invention is 30 designed to have the lag-time of about 2 hours, about 4 hours or about 7 hours, there can be obtained a pharmaceutical preparation wherein release of a medicinal active ingredient is intended to occur at the lower ileum, the ascenfline colon or the transverse colon. If the 35 pharmaceutical preparation of the present invention is designed to have the lag-time being longer than about 7 hours, there can be obtained a pharmaceutical preparation wherein release of a medicinal active ingredient is intended to occur at the lower large intestine such as the descending colon or the sigmoid colon.
The medicinal active ingredient to be included in the above-mentioned core (a) in the present invention 5 is not particularly limited as long as it is orally ~lministerable. Concrete examples of such medicinal active intredient include chemotherapeutic agents, antibiotics, respiratorystimulants, antitussives, expectorants, antimalignanttumor agents, autonomic agents, 10 psychotropic agents, local anesthetics, muscle rel~x~nts, agents affecting digestive organs, antihist~mines, toxicopetic agents, hypnotics, sedatives, antiepileptics, antipyretics, analgesics, antiinflammatoryagents, cardiotonics, antiarrhythmic agents,diuretics, 15 vasodilators, antilipemic agents, nutrients, tonics, alteratives, anticoagulants, agents for liver disease, hypoglycemics, antihypertensives and the like.
The amount of the medicinal active ingredient to be included in the core (a) may be determined to be about 20 0.2 to about 100 w/w %, preferably 0.5 to 50 w/w %, based on a weight of the core (a).
As the pH-independently water-soluble polymer used for the press-coated layer (b), any film-formable polymer usually used in this field which is soluble in an 25 aqueous medium without being influenced by a pH of the aqueous medium can be used. In the present invention, the pH-independently water-soluble polymer may be used alone or in admixture thereof. If necessary, the pH-independently water-soluble polymer may be used in 30 admixture with a water-insoluble polymer, such as ethylcellulose.
Examples of the pH-independently water-soluble polymer include a cellulose derivative such as hydroxypropylcellulose,hydroxypropylmethylcellulose, 35 methylcellulose,hydroxyethylcellulose or methylhydroxyethylcellulose, a synthetic polymer such as polyvinylpyrrolidone, a polysaccharide such as pullulan, a natural high molecular substance such as arabic gum, and 21~21~2 the like.
Among the above-mentioned examples, a cellulose derivative such as hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose or 5 hydroxyethylcellulose, and pullulan are preferable.
Hydroxypropylcellulose and hydroxypropylmethylcellulose are more preferable, and hydroxypropylcellulose is particularly preferable.
Some kinds of the above-mentioned 10 pH-independently water-soluble polymers have a different polymerization degree. The viscosity of the polymer is different depen-ling on a polymerization degree of the substance. In the present invention, the pH-independently water-soluble polymer having any viscosity, i.e.
15 polymerization degree, can be used alone or in admixture of at least two polymers having different viscosities from each other.
For example, in case of using a hydroxypropyl-cellulose as the pH-independently water-soluble polymer, 20 two kinds of hydroxypropylcelluloses having a viscosity of 6 to 10 cps and a viscosity of 150 to 400 cps, respectively, as measured in a 2 % aqueous solution at 20C may be used alone or in admixture thereof. An example of the hydroxypropylcellulose having a viscosity 25 of 6 to 10 cps as measured in a 2 % aqueous solution at 20C, is HPC-L (trade name, available from Nippon Soda Co., Ltd. ). An example of the hydroxypropylcellulose having a viscosity of 150 to 400 cps as measured in a 2 %
aqueous solution at 20C, is HPC-M (trade name, available 30 from Nippon Soda Co., Ltd.). A hydroxypropylcellulose having the above-mentioned viscosity can be suitably used in admixture thereof by determining the mixing ratio to be about 9:1 to about 1:9 by weight.
As an enteric polymer used for the film (c), any 35 film-formable polymer soluble in an aqueous medium of a pH
of not less than 5 and insoluble in an aqueous medium of a pH of less than 5 can be used in the pharmaceutical preparation of the present invention. Examples of such 21421~2 _, g polymer include a cellulose derivative, a polyvinyl derivative, a maleic acid-vinyl compound copolymer, an acrylic copolymer and the like.
Concrete examples of the cellulose derivative 5 include carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, hydroxymethylethylcellulose phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropyl-methylcellulose acetate succinate and the like. Concrete 10 examples of the polyvinyl derivative include polyvinyl alcohol phthalate, polyvinyl butylate phthalate, polyvinyl acetoacetal phthalate and the like. Concrete examples of the maleic acid-vinyl compound copolymer include poly(vinyl acetate, maleic acid anhydride), poly(vinyl 15 butyl ether, maleic acid anhydride), poly{styrene, maleic acid monoester), and the like. Concrete examples of the acrylic copolymer include poly(methyl acrylate, methacrylic acid), poly(styrene, acrylic acid), poly(methyl acrylate, methacrylic acid, octyl acrylate), 20 poly(methacrylic acid, methyl methacrylate) (e.g. Eudragit L and Eudragit S, each being trade name, available from Rohm Pharma, Germany),and the like.
Among these examples, carboxymethylethyl-cellulose, hydroxypropylmethylcellulose phthalate, 25 hydroxypropylmethylcellulose acetate succinate, poly(methacrylic acid, methyl methacrylate) and the like are preferably used as the enteric polymer, and particularly carboxymethylethylcellulose, hydroxypropylmethylcellulose phthalate and 30 hydroxypropylmethylcellulose acetate succinate are preferable. The above-mentioned enteric polymer can be used alone or in admixture thereof.
Additionally, in the above-mentioned core (a), the press-coated layer (b) and the film (c) of the 35 pharmaceutical preparation of the present invention, various additives such as an excipient, a binder, a disintegrant, a lubricant and an aggregation-preventing agent which are generally used in this field may be included, if desired.
Concrete examples of the excipient include saccharide such as sucrose, lactose, mannitol or glucose, starch, crystalline cellulose, calcium phosphate, 5 calcium sulfate and the like. Concrete examples of the binder include polyvinylalcohol, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, glucose, sucrose, lactose, maltose, dextrin, sorbitol, mannitol, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, apolyethyleneglycol, arabic gum, gelatin, agar, starch and the like. Concrete examples of the disintegrant include calcium carboxymethylcellulose, sodium carboxymethylstarch, corn starch, hydroxypropylstarch, partially pregelatinized starch, low-substituted hydroxypropylcellulose, polyvinylpyrrolidone, calcuim cross-linked carboxymethyl-cellulose and the like. Concrete examples of the lubricant and the aggregation-preventing agent are, for example, talc, magnesium stearate, calcium stearate, 20 colloidal silicon dioxide, stearic acid, a wax, a hydrogenated oil, a polyethyleneglycol, sodium benzoate and the like.
The lag-time, the time required until the release of the medicinal active ingredient starts in the 25 intestine or in the second fluid (pH 6.8) described in JPXII, can be controlled by varying the press-coated layer (b) as below. For exmaple, if the amount of the press-coated layer (b) is increased (or decreased), the lag-time can be prolonged (or reduced). In case that the 3 0 coating amount of the press-coated layer (b) is almost constant, if a pH-independently water-soluble polymer having larger (or smaller) polymerization degree, i.e.
viscosity, is used for the press-coated layer (b), the lag-time can be prolonged (or reduced). Moreover, in 35 case that two or more kinds of the pH-independently water-soluble polymer having different viscosities are used in admixture thereof, the lag-time can be also varied according to the mixing ratio. Namely, the lag-time in 21421g2 the pharmaceutical preparation of the present invention can be suitably controlled to be a desired length by employing a proper combination of the coating amount of the press-coated layer (b), the kind and viscosity of the 5 pH-independently water-soluble polymer, the mixing ratio, and the like.
The dosage form of the pharmaceutical preparation of the present invention is preferably a tablet. The size of the pharmaceutical preparation is not 10 particularly limited, however, the diameter thereof is preferably 4 to 16 mm, more preferably 6 to 12 mm.
The form of the core (a) is preferably a tablet.
The size of the core (a) is not particularly limited, however, the diameter thereof is preferably 3 to 15 mm, 15 more preferably 5 to 8 mm.
In the pharmaceutical preparation of the present invention, the thickness of the press-coated layer (b) can be selected without any limitation. The thickness of the press-coated layer (b) is usually determined to be 0. 4 20 to 3 mm, preferably 0. 5 to 1. 5 mm. The coating amount of the press-coated layer (b) corresponding to the above-mentioned thickness, varying according to the size of the core (a), is usually about 150 to about 600 w/w %, preferably 200 to 400 w/w % based on a weight of the core 25 (a).
The coating amount of the film (c), varying according to the enteric polymer used, is usually about 5 to about 50 w/w %, preferably 7 to 20 w/w %, based on a total weight of the core (a) and the press-coated layer 30 (b)-The preparation of the core (a) can be carriedout according to the usual procedure for the preparation, for example, as described in Lemingtons Pharmaceutical Sciences, 17, (Mack Publishing Company, published in 35 1985). For example, in case of preparing a tablet as a core, the tablet can be obtained by tabletting a medicinal active ingredient alone, or if necessary, in admixture with other suitable additives such as an 21~2142 excipient, a binder and a lubricant. If necessary, the above-mentioned medicinal active ingredient or mixture is granulated according to a usual method before the tabletting process.
The press-coating to form the press-coated layer (b) around the core (a) is carried out according to a usual method in this field, for instance, a compression molding method such as a press-coating method or a dry coating method, and the like. For example, the press-coated layer can be formed by press-coating the core (a) with a pH-independently water-soluble polymer alone, or if necessary, in admixture with other suitable additives such as an excipient, a binder, a lubricant and a fluidizing agent. If necessary, the above-mentioned polymer or mixture is granulated according to a usual method before the press-coating process. Then, the press-coated layer is provided on the core. The press-coating can be suitably carried out by means of a press-coating m~chine or a tabletting m~chine generally 20 used, under the conditions such that the compressing pressure is, for instance, 200 to 1200 kg/cm2 and the compressing rate is 1 to 20 mm/minute.
The coating of the press-coated layer (b) with the film (c) can be carried out according to a process 25 usually used in this field such as a fluidizing coating process, a pan coating process or a tllmhling and fluidizing coating process, by means of, for example, a fluidizing coating apparatus, a pan coating apparatus, a tllmhling and fluidizing coating and granulating apparatus 30 or the like. Both an aqueous coating method and a non-aqueous coating method generally used in this field can be employed for the above-mentioned coating. In addition, a plasticizer, an aggregation-preventing agent and the like which are usually used can be suitably added 35 to the coating solution. Alternatively, the coating with the film (c) can be carried out by the press-coating process as mentioned above.
The present invention is more specifically 21421~2 described and explained by means of the following Examples and Experimental Examples. It is to be understood that the present invention is not limited to the Examples, and various changes and modifications may be made in the 5 invention without departing from the spirit and scope thereof.
Example 1 Diltiazem hydrochloride (300 g) and corn starch 10 (200 g) were mixed together. The mixture was granulated according to a wet granulation method using a bin-ling solution ( 180 g) of polyvinylpyrrolidone (trade name:
Kollidon 30, available from BASF) (90 g) dissolved in ethanol (90 g). The obtained granules were dried and 15 shieved to obtain granules for tabletting (585 g). A part of thus obtained granules for tabletting (530 g), calcium citrate (120 g), calcium carboxymethylcellulose (trade name: ECG-505, available from Gotoku Chemical Co., Ltd.) (40 g) and magnesium stearate (10 g) were mixed 20 together. The mixture was tabletted by means of a rotary tabletting m~chine (F-9 Type, made by Kikusui Seisakusho Ltd. ) to obtain a plain tablet (a core tablet) having a diameter of 6 mm and a weight of 70 mg.
The obtained plain tablet was press-coated with 25 a mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ), and hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
30 in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mi~ing ratio, by weight (w/w) (hereinafter referred to as "the mi~in~ ratio") 9:1) in a coating amount of 200 mg per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui 35 Seisakusho Ltd.) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was spray-coated with a 8 w/w % coating solution of 21421~2 -hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mixing ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 5 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 10 preparation of the present invention, a dissolution test (puddle method) was carried out with the first fluid of the test in JPXII (pH 1. 2~ and the second fluid of the test in JPXII (pH 6.8) according to the description of the dissolution test in JPXII. The dissolution test was 15 carried out using 900 mQ of the dissolution fluid at 37C
and at the rotation speed of 100 rpm.
The results of the test is shown in Fig. 1. As it is clear from the dissolution pattern of diltiazem hydrochloride being a medicinal active ingredient, in the 20 first fluid, the medicinal active ingredient was not released at all for long time (at least 12 hours), which means that the acid resistance of the pharmaceutical preparation was maintained sufficiently. In the second fluid, the medicinal active ingredient was quickly 25 released after the lag-time of about 3 hours in a pulsatile dissolution pattern.
Example 2 The plain tablet cont~ining diltiazem 3 0 hydrochloride obtained in Example 1 was press-coated with a mixture of powder of hydroxypropylcellulose (trade name: HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ) and hydroxypropylcellulose 35 (trade name: HPC-M, having a viscosity of 150 to- 400 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mixing ratio, 8:2) in a coating amount of 200 mg per tablet by means of a 21421~2 -press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was 5 spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mixing ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 10 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 15 preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 5 hours.
Example 3 The plain tablet cont~ining diltiazem hydrochloride obtained in Example 1 was press-coated with a mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ) and hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mixing ratio, 6:4) in a coating amount of 200 mg per tablet by means of a press-coating m~chine. (Correct 1 8HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained perss-coated tablet was spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., 21~2142 Ltd.) and triethyl citrate (the mixing ratio, 10: 1) dissolved in 80 w/w % ethanol, in a coating amount of 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
5 Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
10 under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 8 hours.
Example 4 5-Aminosalicylic acid (300 g) and corn starch (200 g) were mixed together. The mixture was granulated according to a wet granulation method using a bin(ling solution (180 g) of polyvinylpyrrolidone (trade name:
Kollidon 30, available from BASF) (90 g) dissolved in 20 ethanol (90 g). The obtained granules were dried and shieved to obtain granules for tabletting (585 g). A part of thus obtained granules for tabletting (530 g), calcium citrate (120 g), calcium carboxymethylcellulose (trade name: ECG-505, available from Gotoku Chemical Co., 25 Ltd.) (40 g) and magnesium stearate (10 g) were mixed together. The mixture was tabletted by means of a rotary tabletting m~chine (F-9 Type, made by Kikusui Seisakusho Ltd. ) to obtain a plain tablet (a core tablet) having a diameter of 6 mm and a weight of 70 mg.
The obtained plain tablet was press-coated with a mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ) and hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mixing ratio, 9: 1) in a coating amount of 200 mg per tablet by means of a press-coating m~chi"e (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd.) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was 5 spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mixing ratio, 10: 1) dissolved in 80 w/w % ethanol, in a coating amount of 30 10 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 15 preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 3 hours.
Example 5 The plain tablet containing 5-aminosalicylic acid obtained in Example 4 was press-coated with a mixture of powder of hydroxypropylcellulose (trade name:
25 HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ), hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, available from Nippon Soda 30 Co., Ltd.) and lactose (the mi~in~ ratio, 3:2:2) in a coating amount of 200 mg - per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was spray-coated with a 8 w/w % coating solution of carboxymethylethylcellulose (trade name: CMEC, available from Freund Industrial Co., Ltd. ) and triacetin (the 21421~2 mi~ing ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind. Co., Ltd. ) to obtain a pharmaceutical 5 preparation of the present invention.
With respect to thus obtained pharmaceutical preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second 10 fluid, the medicinal active ingredient was quickly released after the lag-time of about 5 hours.
Example 6 The plain tablet cont~ining 5-aminosalicylic 15 acid obtained in Example 4 was press-coated with hydroxypropylmethylcellulose (trade name: Metolose 60SH-400, available from The Shin-etsu Chemical Co., Ltd.) in a coating amount of 200 mg per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by 20 Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose phthalate (trade name:
25 HPMCP, available from The Shin-etsu Chemical Co., Ltd. ) dissolved in 80 w/w % ethanol, in a coating amount of 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the 30 present invention.
With respect to thus obtained pharmaceutical preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second 35 fluid, the medicinal active ingredient was quickly released after the lag-time of about 4 hours.
Example 7 21~2142 -The plain tablet cont~ining 5-aminosalicylic acid obtained in Example 4 was press-coated with hydroxypropylmethylcellulose (trade name: Metolose 60SH-400, available from The Shin-etsu Chemical Co., Ltd.) 5 in a coating amount of 200 mg per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was 10 spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mi~in~ ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 15 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 20 preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 4 hours.
Experimental Example 1 With respect to the pharmaceutical preparation obtained in Example 1, after immersing in the first fluid of the test in JPXII for a certain time, a dissolution 30 test was carried out with the second fluid of the test in JPXII (the other conditions were the same as in ~mple 1). The results of the test are shown in Fig. 2. The dissolution patterns A, B and C represent the results of the dissolution test with the second fluid using the 35 pharmaceutical preparations previously immersed in the first fluid for 0, 8 and 16 hours, respectively. As it is clear from the dissolution patterns of diltiazem hydrochloride, independent on the immersed time in the first fluid, each pharmaceutical preparation showed almost the same dissolution pattern of which the lag-time is about 3 hours in the second fluid.
The above-mentioned results suggest that when 5 the pharmaceutical preparation of the present invention is orally ~dministered, without being influenced by the variation of the length of the residence time of the pharmaceutical preparation in the stomach, the eventual release of the medicinal active ingredient starts only at 10 about 3 hours after re~ching the small intestine.
Experimental F~mple 2 Three kinds of the pharmaceutical preparations of the present invention were prepared by the same way as 15 in F~r~mple 1 except that the amount per tablet of the mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, av~ ble from Nippon Soda Co., Ltd.) and hydroxypropylcellulose (trade name: HPC-M, 20 having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, av~ ble from Nippon Soda Co., Ltd.) (the mi~ing ratio, 9:1) was changed to 200 mg, 160 mg and 140 mg, respectively. With respect to these pharmaceutical preparations, dissolution tests were 25 carried out with the second fluid of the test in JPXII (the other conditions were the same as in Example 1). The results are shown in Fig. 3. The pharmaceutical preparations A, B and C represent the obtained pharmaceutical preparations wherein the amount of the 30 press-coated layer per tablet is 200 mg, 160 mg and 140 mg, respectively. All pharmaceutical preparations A, B and C
showed unique pulsatile dissolution patterns. The lag-times in each pharmaceutical preparation were about 3 hours, about 2 hours and about 1 hour, respectively.
35 That is, the amount of the press-coated layer of these pharmaceutical p~ epa~ ations was lesser, the lag-time was shorter.
These results suggest that when these three kinds of the pharmaceutical preparations having different amounts of the press-coated layer are orally ~(lministered, the release of the medicinal active ingredient can start at a different site in the intestine, individually.
In addition to the ingredients used in the Examples, other ingredients can be used in the Examples as set forth in the specification to obtain substantially the same results.
MEDICINAL ACTIVE INGREDIENT AT TARGETED SITE IN
INTESTINAL TRACT
BACKGROUND OF THE INVENTION
The present invention relates to a pharmaceutical preparation controlled to release a medicinal active ingredient at a targeted site in the 5 gastrointestinal tract, and more particularly to a pharmaceutical preparation for oral ~(lministration from which a medicinal active ingredient can be selectively delivered to any specific site in the intestinal tract.
Selective delivery of a medicinal active 10 ingredient to a specific site in the intestinal tract has been desired in drug therapies, for instance, a local therapy for inflammatory disease in the intestinal tract such as ulcerative colitis or Crohn s disease, or an oral ~1ministrative therapy with a medicinal compound of a 15 peptide which is apt to be decomposed chemically or enzymatically in the intestinal tract, with a medicinal compound of which the absorption site is limited, or with other medicinal compound.
In order to efficiently realize the selective 20 delivery of a medicinal active ingredient to a specific site in the intestinal tract, it is necessary to design a pharmaceutical preparation taking into account the physical and physiological environment in the human gastrointestinal tract and the traveling time of the 25 pharmaceutical preparation in the intestinal tract. With respect to the physical and physiological environment in the gastrointestinal tract, it is recognized that the value of pH in the stomach is usually 1. 8 to 4. 5 in a healthy human and that the value of pH in the intestines 3 0 is 6 . 5 to 7. 5 and the pH does not essentially differ between the small intestine and the large intestine.
According to the results of the widespread research of Davis et al., the residence time of a pharmaceutical preparation in the human stomach is 0.5 to 10 hours and further not only the inter-individual variation thereof is large, but also the residence time is considerably influenced, for example, by feeding, a size of the pharmaceutical preparation to be ~rlministered and the 5 like. However, the traveling time of a pharmaceutical preparation through the small intestine is generally recognized to be 3+1 hours and the inter- and intra-individual variation is relatively small (Journal of Controlled Release, 2, 27-38 (1985)).
With respect to a method by which a medicinal active ingredient can be selectively delivered to a specific site in the intestinal tract, hitherto various researches have been done. There have been proposed a pharmaceutical preparation wherein a sustained release 15 pharmaceutical preparation is coated with an enteric coating (Annals of the New York Ac~-lemy of Science, 618, 428-440 (1991)), a pharmaceutical preparation obtained by utilizing a technique for controlling the starting time of the release (Chemical & Pharmaceutical Bulletin, 40, 20 3036-3041 (1992)) and the like, as well as pharmaceutical preparations obtained by using known techniques such as an enteric pharmaceutical preparation and a sustained release pharmaceutical preparation.
However, every conventional method has a problem 25 such as insufficient site-selectivity or poor practicality due to peculiarity of the material to be used. For example, in case of using the enteric pharmaceutical preparation, the release of a medicinal active ingredient starts abruptly at the upper small intestine resulting in 30 consumption of almost of the medicinal active ingredient by absorption or decomposition before the medicinal active ingredient reaches the targeted site in the intestine, although the release of the medicinal active ingredient can be effectively suppressed in the stomach. In case of 35 using the sustained release pharmaceutical preparation, a considerable amount of a medicinal active ingredient is released when the pharmaceutical preparation stays in the stomach and passes through the small intestine because the _ -- 3 medicinal active ingredient is continuously released.
Further, in order to release a medicinal active ingredient at the large intestine, there has been recently developed a system utilizing the ecosystem of specific microorganisms in the large intestine. For example, in a pharmaceutical preparation wherein a composition containing a medicinal active ingredient is coated with a novel polymer having an azo group, or the composition cont~ining a medicinal active ingredient is dispersed in the new polymer having an azo group to form a matrix type of pharmaceutical preparation (Science, 233, 1081-1084 ( 1986)), the polymer is decomposed in the large intestine by enterobacteria having azo-reductase activity and the medicinal active ingredient is thereby released at the large intestine. However, for practical use, there are still many problems to be solved, for example, regarding the safety of the polymer itself, the controllability of the decomposition rate thereof, and the like.
An object of the present invention is to solve the above-mentioned problems in the conventional pharmaceutical preparations, and to provide a pharmaceutical preparation for oral ~rlministration by which a medicinal active ingredient can be effectively 25 released at a targeted site in the intestinal tract.
This and the other objects of the present invention will become apparent from the description hereinafter.
SUMl\~ARY OF THE INVENTION
In accordance with the present invention, there is provided a pharmaceutical preparation for oral ~lministration comprising (a) a core cont~ining a medicinal active ingredient, 3 5 (b) a press-coated layer comprising a pH-independently water-soluble polymer, said layer being provided around the core and (c) a film comprising an enteric polymer, said film being 21421~2 provided around the press-coated layer.
The pharmaceutical preparation of the present invention has the following characteristics: when the pharmaceutical preparation is orally ~rlmini~tered, the 5 release of a medicinal active ingredient does not occur at all during residence of the pharmaceutical preparation in the stomach and, after discharge from the stomach, until the preparation reaches a desirable targeted site in the intestine and thereafter, the release of the ingredient 10 starts rapidly. In case of using a medicinal active ingredient as a drug required to be selectively delivered to a specific site in the intestinal tract, an excellent pharmaceutical preparation having high av~ bility can be provided.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graph showing the result of the dissolution test with the first fluid and the second fluid of the dissolution test in Japanese Pharmacopoeia XII
20 (hereinafter referred to as JPXII) using a pharmaceutical preparation in Example 1.
Fig. 2 is a graph showing the result of the dissolution test with the second fluid of the dissolution test in JPXII using a pharmaceutical preparation after 25 immersing in the first fluid of the dissolution test in JPXII for a certain time in Experimental Example 1.
Fig. 3 is a graph showing the result of the dissolution test with the second fluid of the dissolution test in JPXII using three kinds of pharmaceutical 30 preparations having different coating amounts of the press-coated layer in Experimental Example 2.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a pharmaceutical 35 preparation from which a medicinal active ingredient can be selectively released at a targeted site in the intestinal tract, by comhining an enteric polymer, which dissolves dependent on a value of pH, and a press-coated 21~21~2 layer comprising a pH-independently water-soluble polymer.
In the pharmaceutical preparation of the present invention, the concrete structure thereof can be suitably selected so that a medicinal active ingredient can be 5 released at the desirable targeted site in the intestinal tract.
In the pharmaceutical preparation of the present invention, the functions of the film (c) comprising an enteric polymer are to prevent the penetration of water 10 during residence of the pharmaceutical preparation in the stomach so that the contents [ core (a) and press-coated layer (b)] thereof can be protected, and to quickly dissolve according as the surrounding pH increases after discharge of the pharmaceutical preparation from the 15 stomach so that the contents are forwarded to the upper small intestine. The press-coated layer (b) perfectly prevents the penetration of water into the core (a), unless the press-coated layer (b) dissolves, and therefore the press-coated layer (b) suppresses the release of 20 the medicinal active ingredient in the intestine after discharge of the pharmaceutical preparation from the stomach. Namely, the press-coated layer (bj is capable of suppressing the release of the medicinal active ingredient in the intestine until the pharmaceutical preparation 25 reaches near the desirable targeted site.
In order to sufficiently exhibit the above-mentioned capacity in the pharmaceutical preparation of the present invention, it is desirable to determine the coating amount of the film (c) so that the pharmaceutical 30 preparation has sufficient acid resistance and the film (c) prevents the penetration of water into the pharmaceutical preparation during residence in the stomach. It is also desirable to determine the time required for dissolution of the press-coated layer (b) 35 in the intestine so that the press-coated layer (b) can substantially suppress the release of the medicinal active ingredient until the pharmaceutical preparation re~ches near the desirable targeted site in the intestine.
21421~2 From the above-mentioned viewpoints, it is desirable that the coating amount of the film (c) is usually determined so that the film (c) prevents the penetration of water during residence in the stomach for a 5 period of about 10 hours which is recognized as the m~ximum residence time of a pharmaceutical preparation in the stomach, and that in case of targeting the upper large intestine, the coating amount of the press-coated layer (b) is determined so that the press-coated layer (b) can 10 suppress the release of a medicinal active ingredient in the intestines for about 3+1 hours which is recognized as a general traveling time of a pharmaceutical preparation through the small intestine.
The pharmaceutical preparation of the present 15 invention can be suitably designed so that when a dissolution test is carried out according to the dissolution test (puddle method; 37C; 100 rpm; 900 mQ of dissolution fluid) of JPXII (refer to Example 1), release of a medicinal active ingredient is substantially 20 suppressed for at least 10 hours in the first fluid (pH 1. 2), and the release of the medicinal active ingredient is substantially suppressed for at least about 2 hours in the second fluid (pH 6.8) and thereafter the release of the medicinal active ingredient starts quickly.
25 The time required to start the release of the medicinal active ingredient (hereinafter referred to as alag-time" ) in the second fluid is set to meet the desired target-site in the intestinal tract. For example, in case that the pharmaceutical preparation of the present invention is 30 designed to have the lag-time of about 2 hours, about 4 hours or about 7 hours, there can be obtained a pharmaceutical preparation wherein release of a medicinal active ingredient is intended to occur at the lower ileum, the ascenfline colon or the transverse colon. If the 35 pharmaceutical preparation of the present invention is designed to have the lag-time being longer than about 7 hours, there can be obtained a pharmaceutical preparation wherein release of a medicinal active ingredient is intended to occur at the lower large intestine such as the descending colon or the sigmoid colon.
The medicinal active ingredient to be included in the above-mentioned core (a) in the present invention 5 is not particularly limited as long as it is orally ~lministerable. Concrete examples of such medicinal active intredient include chemotherapeutic agents, antibiotics, respiratorystimulants, antitussives, expectorants, antimalignanttumor agents, autonomic agents, 10 psychotropic agents, local anesthetics, muscle rel~x~nts, agents affecting digestive organs, antihist~mines, toxicopetic agents, hypnotics, sedatives, antiepileptics, antipyretics, analgesics, antiinflammatoryagents, cardiotonics, antiarrhythmic agents,diuretics, 15 vasodilators, antilipemic agents, nutrients, tonics, alteratives, anticoagulants, agents for liver disease, hypoglycemics, antihypertensives and the like.
The amount of the medicinal active ingredient to be included in the core (a) may be determined to be about 20 0.2 to about 100 w/w %, preferably 0.5 to 50 w/w %, based on a weight of the core (a).
As the pH-independently water-soluble polymer used for the press-coated layer (b), any film-formable polymer usually used in this field which is soluble in an 25 aqueous medium without being influenced by a pH of the aqueous medium can be used. In the present invention, the pH-independently water-soluble polymer may be used alone or in admixture thereof. If necessary, the pH-independently water-soluble polymer may be used in 30 admixture with a water-insoluble polymer, such as ethylcellulose.
Examples of the pH-independently water-soluble polymer include a cellulose derivative such as hydroxypropylcellulose,hydroxypropylmethylcellulose, 35 methylcellulose,hydroxyethylcellulose or methylhydroxyethylcellulose, a synthetic polymer such as polyvinylpyrrolidone, a polysaccharide such as pullulan, a natural high molecular substance such as arabic gum, and 21~21~2 the like.
Among the above-mentioned examples, a cellulose derivative such as hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose or 5 hydroxyethylcellulose, and pullulan are preferable.
Hydroxypropylcellulose and hydroxypropylmethylcellulose are more preferable, and hydroxypropylcellulose is particularly preferable.
Some kinds of the above-mentioned 10 pH-independently water-soluble polymers have a different polymerization degree. The viscosity of the polymer is different depen-ling on a polymerization degree of the substance. In the present invention, the pH-independently water-soluble polymer having any viscosity, i.e.
15 polymerization degree, can be used alone or in admixture of at least two polymers having different viscosities from each other.
For example, in case of using a hydroxypropyl-cellulose as the pH-independently water-soluble polymer, 20 two kinds of hydroxypropylcelluloses having a viscosity of 6 to 10 cps and a viscosity of 150 to 400 cps, respectively, as measured in a 2 % aqueous solution at 20C may be used alone or in admixture thereof. An example of the hydroxypropylcellulose having a viscosity 25 of 6 to 10 cps as measured in a 2 % aqueous solution at 20C, is HPC-L (trade name, available from Nippon Soda Co., Ltd. ). An example of the hydroxypropylcellulose having a viscosity of 150 to 400 cps as measured in a 2 %
aqueous solution at 20C, is HPC-M (trade name, available 30 from Nippon Soda Co., Ltd.). A hydroxypropylcellulose having the above-mentioned viscosity can be suitably used in admixture thereof by determining the mixing ratio to be about 9:1 to about 1:9 by weight.
As an enteric polymer used for the film (c), any 35 film-formable polymer soluble in an aqueous medium of a pH
of not less than 5 and insoluble in an aqueous medium of a pH of less than 5 can be used in the pharmaceutical preparation of the present invention. Examples of such 21421~2 _, g polymer include a cellulose derivative, a polyvinyl derivative, a maleic acid-vinyl compound copolymer, an acrylic copolymer and the like.
Concrete examples of the cellulose derivative 5 include carboxymethylethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, hydroxymethylethylcellulose phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropyl-methylcellulose acetate succinate and the like. Concrete 10 examples of the polyvinyl derivative include polyvinyl alcohol phthalate, polyvinyl butylate phthalate, polyvinyl acetoacetal phthalate and the like. Concrete examples of the maleic acid-vinyl compound copolymer include poly(vinyl acetate, maleic acid anhydride), poly(vinyl 15 butyl ether, maleic acid anhydride), poly{styrene, maleic acid monoester), and the like. Concrete examples of the acrylic copolymer include poly(methyl acrylate, methacrylic acid), poly(styrene, acrylic acid), poly(methyl acrylate, methacrylic acid, octyl acrylate), 20 poly(methacrylic acid, methyl methacrylate) (e.g. Eudragit L and Eudragit S, each being trade name, available from Rohm Pharma, Germany),and the like.
Among these examples, carboxymethylethyl-cellulose, hydroxypropylmethylcellulose phthalate, 25 hydroxypropylmethylcellulose acetate succinate, poly(methacrylic acid, methyl methacrylate) and the like are preferably used as the enteric polymer, and particularly carboxymethylethylcellulose, hydroxypropylmethylcellulose phthalate and 30 hydroxypropylmethylcellulose acetate succinate are preferable. The above-mentioned enteric polymer can be used alone or in admixture thereof.
Additionally, in the above-mentioned core (a), the press-coated layer (b) and the film (c) of the 35 pharmaceutical preparation of the present invention, various additives such as an excipient, a binder, a disintegrant, a lubricant and an aggregation-preventing agent which are generally used in this field may be included, if desired.
Concrete examples of the excipient include saccharide such as sucrose, lactose, mannitol or glucose, starch, crystalline cellulose, calcium phosphate, 5 calcium sulfate and the like. Concrete examples of the binder include polyvinylalcohol, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, glucose, sucrose, lactose, maltose, dextrin, sorbitol, mannitol, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, apolyethyleneglycol, arabic gum, gelatin, agar, starch and the like. Concrete examples of the disintegrant include calcium carboxymethylcellulose, sodium carboxymethylstarch, corn starch, hydroxypropylstarch, partially pregelatinized starch, low-substituted hydroxypropylcellulose, polyvinylpyrrolidone, calcuim cross-linked carboxymethyl-cellulose and the like. Concrete examples of the lubricant and the aggregation-preventing agent are, for example, talc, magnesium stearate, calcium stearate, 20 colloidal silicon dioxide, stearic acid, a wax, a hydrogenated oil, a polyethyleneglycol, sodium benzoate and the like.
The lag-time, the time required until the release of the medicinal active ingredient starts in the 25 intestine or in the second fluid (pH 6.8) described in JPXII, can be controlled by varying the press-coated layer (b) as below. For exmaple, if the amount of the press-coated layer (b) is increased (or decreased), the lag-time can be prolonged (or reduced). In case that the 3 0 coating amount of the press-coated layer (b) is almost constant, if a pH-independently water-soluble polymer having larger (or smaller) polymerization degree, i.e.
viscosity, is used for the press-coated layer (b), the lag-time can be prolonged (or reduced). Moreover, in 35 case that two or more kinds of the pH-independently water-soluble polymer having different viscosities are used in admixture thereof, the lag-time can be also varied according to the mixing ratio. Namely, the lag-time in 21421g2 the pharmaceutical preparation of the present invention can be suitably controlled to be a desired length by employing a proper combination of the coating amount of the press-coated layer (b), the kind and viscosity of the 5 pH-independently water-soluble polymer, the mixing ratio, and the like.
The dosage form of the pharmaceutical preparation of the present invention is preferably a tablet. The size of the pharmaceutical preparation is not 10 particularly limited, however, the diameter thereof is preferably 4 to 16 mm, more preferably 6 to 12 mm.
The form of the core (a) is preferably a tablet.
The size of the core (a) is not particularly limited, however, the diameter thereof is preferably 3 to 15 mm, 15 more preferably 5 to 8 mm.
In the pharmaceutical preparation of the present invention, the thickness of the press-coated layer (b) can be selected without any limitation. The thickness of the press-coated layer (b) is usually determined to be 0. 4 20 to 3 mm, preferably 0. 5 to 1. 5 mm. The coating amount of the press-coated layer (b) corresponding to the above-mentioned thickness, varying according to the size of the core (a), is usually about 150 to about 600 w/w %, preferably 200 to 400 w/w % based on a weight of the core 25 (a).
The coating amount of the film (c), varying according to the enteric polymer used, is usually about 5 to about 50 w/w %, preferably 7 to 20 w/w %, based on a total weight of the core (a) and the press-coated layer 30 (b)-The preparation of the core (a) can be carriedout according to the usual procedure for the preparation, for example, as described in Lemingtons Pharmaceutical Sciences, 17, (Mack Publishing Company, published in 35 1985). For example, in case of preparing a tablet as a core, the tablet can be obtained by tabletting a medicinal active ingredient alone, or if necessary, in admixture with other suitable additives such as an 21~2142 excipient, a binder and a lubricant. If necessary, the above-mentioned medicinal active ingredient or mixture is granulated according to a usual method before the tabletting process.
The press-coating to form the press-coated layer (b) around the core (a) is carried out according to a usual method in this field, for instance, a compression molding method such as a press-coating method or a dry coating method, and the like. For example, the press-coated layer can be formed by press-coating the core (a) with a pH-independently water-soluble polymer alone, or if necessary, in admixture with other suitable additives such as an excipient, a binder, a lubricant and a fluidizing agent. If necessary, the above-mentioned polymer or mixture is granulated according to a usual method before the press-coating process. Then, the press-coated layer is provided on the core. The press-coating can be suitably carried out by means of a press-coating m~chine or a tabletting m~chine generally 20 used, under the conditions such that the compressing pressure is, for instance, 200 to 1200 kg/cm2 and the compressing rate is 1 to 20 mm/minute.
The coating of the press-coated layer (b) with the film (c) can be carried out according to a process 25 usually used in this field such as a fluidizing coating process, a pan coating process or a tllmhling and fluidizing coating process, by means of, for example, a fluidizing coating apparatus, a pan coating apparatus, a tllmhling and fluidizing coating and granulating apparatus 30 or the like. Both an aqueous coating method and a non-aqueous coating method generally used in this field can be employed for the above-mentioned coating. In addition, a plasticizer, an aggregation-preventing agent and the like which are usually used can be suitably added 35 to the coating solution. Alternatively, the coating with the film (c) can be carried out by the press-coating process as mentioned above.
The present invention is more specifically 21421~2 described and explained by means of the following Examples and Experimental Examples. It is to be understood that the present invention is not limited to the Examples, and various changes and modifications may be made in the 5 invention without departing from the spirit and scope thereof.
Example 1 Diltiazem hydrochloride (300 g) and corn starch 10 (200 g) were mixed together. The mixture was granulated according to a wet granulation method using a bin-ling solution ( 180 g) of polyvinylpyrrolidone (trade name:
Kollidon 30, available from BASF) (90 g) dissolved in ethanol (90 g). The obtained granules were dried and 15 shieved to obtain granules for tabletting (585 g). A part of thus obtained granules for tabletting (530 g), calcium citrate (120 g), calcium carboxymethylcellulose (trade name: ECG-505, available from Gotoku Chemical Co., Ltd.) (40 g) and magnesium stearate (10 g) were mixed 20 together. The mixture was tabletted by means of a rotary tabletting m~chine (F-9 Type, made by Kikusui Seisakusho Ltd. ) to obtain a plain tablet (a core tablet) having a diameter of 6 mm and a weight of 70 mg.
The obtained plain tablet was press-coated with 25 a mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ), and hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
30 in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mi~ing ratio, by weight (w/w) (hereinafter referred to as "the mi~in~ ratio") 9:1) in a coating amount of 200 mg per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui 35 Seisakusho Ltd.) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was spray-coated with a 8 w/w % coating solution of 21421~2 -hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mixing ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 5 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 10 preparation of the present invention, a dissolution test (puddle method) was carried out with the first fluid of the test in JPXII (pH 1. 2~ and the second fluid of the test in JPXII (pH 6.8) according to the description of the dissolution test in JPXII. The dissolution test was 15 carried out using 900 mQ of the dissolution fluid at 37C
and at the rotation speed of 100 rpm.
The results of the test is shown in Fig. 1. As it is clear from the dissolution pattern of diltiazem hydrochloride being a medicinal active ingredient, in the 20 first fluid, the medicinal active ingredient was not released at all for long time (at least 12 hours), which means that the acid resistance of the pharmaceutical preparation was maintained sufficiently. In the second fluid, the medicinal active ingredient was quickly 25 released after the lag-time of about 3 hours in a pulsatile dissolution pattern.
Example 2 The plain tablet cont~ining diltiazem 3 0 hydrochloride obtained in Example 1 was press-coated with a mixture of powder of hydroxypropylcellulose (trade name: HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ) and hydroxypropylcellulose 35 (trade name: HPC-M, having a viscosity of 150 to- 400 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mixing ratio, 8:2) in a coating amount of 200 mg per tablet by means of a 21421~2 -press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was 5 spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mixing ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 10 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 15 preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 5 hours.
Example 3 The plain tablet cont~ining diltiazem hydrochloride obtained in Example 1 was press-coated with a mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ) and hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mixing ratio, 6:4) in a coating amount of 200 mg per tablet by means of a press-coating m~chine. (Correct 1 8HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained perss-coated tablet was spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., 21~2142 Ltd.) and triethyl citrate (the mixing ratio, 10: 1) dissolved in 80 w/w % ethanol, in a coating amount of 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
5 Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
10 under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 8 hours.
Example 4 5-Aminosalicylic acid (300 g) and corn starch (200 g) were mixed together. The mixture was granulated according to a wet granulation method using a bin(ling solution (180 g) of polyvinylpyrrolidone (trade name:
Kollidon 30, available from BASF) (90 g) dissolved in 20 ethanol (90 g). The obtained granules were dried and shieved to obtain granules for tabletting (585 g). A part of thus obtained granules for tabletting (530 g), calcium citrate (120 g), calcium carboxymethylcellulose (trade name: ECG-505, available from Gotoku Chemical Co., 25 Ltd.) (40 g) and magnesium stearate (10 g) were mixed together. The mixture was tabletted by means of a rotary tabletting m~chine (F-9 Type, made by Kikusui Seisakusho Ltd. ) to obtain a plain tablet (a core tablet) having a diameter of 6 mm and a weight of 70 mg.
The obtained plain tablet was press-coated with a mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ) and hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, available from Nippon Soda Co., Ltd.) (the mixing ratio, 9: 1) in a coating amount of 200 mg per tablet by means of a press-coating m~chi"e (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd.) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was 5 spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mixing ratio, 10: 1) dissolved in 80 w/w % ethanol, in a coating amount of 30 10 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 15 preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 3 hours.
Example 5 The plain tablet containing 5-aminosalicylic acid obtained in Example 4 was press-coated with a mixture of powder of hydroxypropylcellulose (trade name:
25 HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, available from Nippon Soda Co., Ltd. ), hydroxypropylcellulose (trade name: HPC-M, having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, available from Nippon Soda 30 Co., Ltd.) and lactose (the mi~in~ ratio, 3:2:2) in a coating amount of 200 mg - per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was spray-coated with a 8 w/w % coating solution of carboxymethylethylcellulose (trade name: CMEC, available from Freund Industrial Co., Ltd. ) and triacetin (the 21421~2 mi~ing ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind. Co., Ltd. ) to obtain a pharmaceutical 5 preparation of the present invention.
With respect to thus obtained pharmaceutical preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second 10 fluid, the medicinal active ingredient was quickly released after the lag-time of about 5 hours.
Example 6 The plain tablet cont~ining 5-aminosalicylic 15 acid obtained in Example 4 was press-coated with hydroxypropylmethylcellulose (trade name: Metolose 60SH-400, available from The Shin-etsu Chemical Co., Ltd.) in a coating amount of 200 mg per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by 20 Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose phthalate (trade name:
25 HPMCP, available from The Shin-etsu Chemical Co., Ltd. ) dissolved in 80 w/w % ethanol, in a coating amount of 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the 30 present invention.
With respect to thus obtained pharmaceutical preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second 35 fluid, the medicinal active ingredient was quickly released after the lag-time of about 4 hours.
Example 7 21~2142 -The plain tablet cont~ining 5-aminosalicylic acid obtained in Example 4 was press-coated with hydroxypropylmethylcellulose (trade name: Metolose 60SH-400, available from The Shin-etsu Chemical Co., Ltd.) 5 in a coating amount of 200 mg per tablet by means of a press-coating m~chine (Correct 18HUK-DC Type, made by Kikusui Seisakusho Ltd. ) to obtain a press-coated tablet having a diameter of 9 mm and a weight of 270 mg.
Then, the obtained press-coated tablet was 10 spray-coated with a 8 w/w % coating solution of hydroxypropylmethylcellulose acetate succinate (trade name: HPMCAS-M, available from The Shin-etsu Chemical Co., Ltd.) and triethyl citrate (the mi~in~ ratio, 10:1) dissolved in 80 w/w % ethanol, in a coating amount of 15 30 mg per tablet by means of a fluidized bed coating apparatus (MODEL HCT-MINI HICOATER, made by Freund Ind.
Co., Ltd. ) to obtain a pharmaceutical preparation of the present invention.
With respect to thus obtained pharmaceutical 20 preparation of the present invention, a dissolution test was carried out with the second fluid of the test in JPXII
under the same conditions in Example 1. In the second fluid, the medicinal active ingredient was quickly released after the lag-time of about 4 hours.
Experimental Example 1 With respect to the pharmaceutical preparation obtained in Example 1, after immersing in the first fluid of the test in JPXII for a certain time, a dissolution 30 test was carried out with the second fluid of the test in JPXII (the other conditions were the same as in ~mple 1). The results of the test are shown in Fig. 2. The dissolution patterns A, B and C represent the results of the dissolution test with the second fluid using the 35 pharmaceutical preparations previously immersed in the first fluid for 0, 8 and 16 hours, respectively. As it is clear from the dissolution patterns of diltiazem hydrochloride, independent on the immersed time in the first fluid, each pharmaceutical preparation showed almost the same dissolution pattern of which the lag-time is about 3 hours in the second fluid.
The above-mentioned results suggest that when 5 the pharmaceutical preparation of the present invention is orally ~dministered, without being influenced by the variation of the length of the residence time of the pharmaceutical preparation in the stomach, the eventual release of the medicinal active ingredient starts only at 10 about 3 hours after re~ching the small intestine.
Experimental F~mple 2 Three kinds of the pharmaceutical preparations of the present invention were prepared by the same way as 15 in F~r~mple 1 except that the amount per tablet of the mixture of powder of hydroxypropylcellulose (trade name:
HPC-L, having a viscosity of 6 to 10 cps as measured at 20C in a 2 % aqueous solution, av~ ble from Nippon Soda Co., Ltd.) and hydroxypropylcellulose (trade name: HPC-M, 20 having a viscosity of 150 to 400 cps as measured at 20C
in a 2 % aqueous solution, av~ ble from Nippon Soda Co., Ltd.) (the mi~ing ratio, 9:1) was changed to 200 mg, 160 mg and 140 mg, respectively. With respect to these pharmaceutical preparations, dissolution tests were 25 carried out with the second fluid of the test in JPXII (the other conditions were the same as in Example 1). The results are shown in Fig. 3. The pharmaceutical preparations A, B and C represent the obtained pharmaceutical preparations wherein the amount of the 30 press-coated layer per tablet is 200 mg, 160 mg and 140 mg, respectively. All pharmaceutical preparations A, B and C
showed unique pulsatile dissolution patterns. The lag-times in each pharmaceutical preparation were about 3 hours, about 2 hours and about 1 hour, respectively.
35 That is, the amount of the press-coated layer of these pharmaceutical p~ epa~ ations was lesser, the lag-time was shorter.
These results suggest that when these three kinds of the pharmaceutical preparations having different amounts of the press-coated layer are orally ~(lministered, the release of the medicinal active ingredient can start at a different site in the intestine, individually.
In addition to the ingredients used in the Examples, other ingredients can be used in the Examples as set forth in the specification to obtain substantially the same results.
Claims (7)
1. A pharmaceutical preparation for oral administration comprising (a) a core containing a medicinal active ingredient, (b) a press-coated layer comprising a pH-independently water-soluble polymer, said layer being provided around the core and (c) a film comprising an enteric polymer, said film being provided around the press-coated layer.
2. The pharmaceutical preparation of Claim 1, wherein the press-coated layer (b) is capable of suppressing release of a medicinal active ingredient until the pharmaceutical preparation reaches near a targeted site in the intestinal tract.
3. The pharmaceutical preparation of Claim 1, wherein release of a medicinal active ingredient is substantially suppressed for at least 10 hours in the first fluid of a dissolution test according to Japanese Pharmacopoeia XII and the release of the medicinal active ingredient is substantially suppressed for at least 2 hours in the second fluid of the test, when the dissolution test is carried out.
4. The pharmaceutical preparation of Claim 1 or 2, wherein a coating amount of the film (c) is 5 to 50 %
by weight based on a total weight of the core (a) and the press-coated layer (b), and a coating amount of the press-coated layer (b) is 150 to 600 % by weight based on a weight of the core (a).
by weight based on a total weight of the core (a) and the press-coated layer (b), and a coating amount of the press-coated layer (b) is 150 to 600 % by weight based on a weight of the core (a).
5. The pharmaceutical preparation of Claim 1, wherein the pH-independently water-soluble polymer is one or more kinds of substances selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose and pullulan.
6. The pharmaceutical preparation of Claim 1, wherein the pH-independently water-soluble polymer is a mixture of two kinds of hydroxypropylcelluloses having a viscosity of 6 to 10 cps and a viscosity of 150 to 400 cps, respectively, as measured in a 2 % aqueous solution at 20°C, in a mixing ratio of 9:1 to 1:9 by weight.
7. The pharmaceutical preparation of Claim 1, 5 or 6, wherein the enteric polymer is carboxymethylethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate or poly(methacrylic acid, methyl methacrylate).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16028/1994 | 1994-02-10 | ||
| JP6016028A JPH07223970A (en) | 1994-02-10 | 1994-02-10 | Releasing formulation at niche in digestive tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2142142A1 true CA2142142A1 (en) | 1995-08-11 |
Family
ID=11905121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002142142A Abandoned CA2142142A1 (en) | 1994-02-10 | 1995-02-09 | Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5614220A (en) |
| EP (1) | EP0671167A1 (en) |
| JP (1) | JPH07223970A (en) |
| KR (1) | KR950031048A (en) |
| CN (1) | CN1116926A (en) |
| CA (1) | CA2142142A1 (en) |
| MX (1) | MX9500885A (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US7070806B2 (en) * | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
| US5851579A (en) * | 1996-10-28 | 1998-12-22 | Eastman Chemical Company | Aqueous enteric coating compositions |
| WO1998026767A2 (en) * | 1996-12-17 | 1998-06-25 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
| US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| JP2000128779A (en) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | Controlled release medicine type preparation |
| ES2197600T3 (en) | 1999-01-29 | 2004-01-01 | Disphar International B.V. | PHARMACEUTICAL COMPOSITIONS. |
| SE9901387D0 (en) * | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| IN190974B (en) * | 1999-09-10 | 2003-09-06 | Ranbaxy Lab Ltd | |
| US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
| DE60116758T2 (en) | 2000-05-18 | 2006-11-02 | Therics, Inc. | Encapsulation of a toxic to a non-toxic region in an oral formulation |
| JP4875277B2 (en) | 2000-06-16 | 2012-02-15 | 田辺三菱製薬株式会社 | Release pH range and / or rate controlling composition |
| US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| SE0003766D0 (en) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| US20020119196A1 (en) * | 2000-12-21 | 2002-08-29 | Narendra Parikh | Texture masked particles containing an active ingredient |
| US6569292B2 (en) | 2001-04-04 | 2003-05-27 | Texas Christian University | Method and device for forming a calcium phosphate film on a substrate |
| WO2004087109A1 (en) * | 2003-03-27 | 2004-10-14 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis |
| US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
| US20060024368A1 (en) * | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
| AR052225A1 (en) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | FORMULATIONS OF MODIFIED RELEASE TABLETS FOR INHIBITORS OF THE PUMP OF PROTONS |
| AR051654A1 (en) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | NEW FORMULATIONS OF MODIFIED RELEASE PELLETS FOR PROTON PUMP INHIBITORS |
| CN101193628A (en) * | 2005-04-12 | 2008-06-04 | 神经化学（国际）有限公司 | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20090036414A1 (en) * | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
| GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| WO2012147100A1 (en) * | 2011-04-25 | 2012-11-01 | Hetero Research Foundation | Extended release compositions of quetiapine |
| GB201420306D0 (en) | 2014-11-14 | 2014-12-31 | Bio Images Drug Delivery Ltd | Compositions |
| TR201722039A2 (en) * | 2017-12-27 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5068110A (en) * | 1987-09-29 | 1991-11-26 | Warner-Lambert Company | Stabilization of enteric coated dosage form |
| IT1230576B (en) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| EP0546593B1 (en) * | 1991-10-30 | 1997-09-03 | Glaxo Group Limited | Multi-layered compositions containing histamine or serotonin antagonists |
| US5167964A (en) * | 1992-02-14 | 1992-12-01 | Warner-Lambert Company | Semi-enteric drug delivery systems and methods for preparing same |
-
1994
- 1994-02-10 JP JP6016028A patent/JPH07223970A/en active Pending
-
1995
- 1995-02-09 MX MX9500885A patent/MX9500885A/en unknown
- 1995-02-09 US US08/385,982 patent/US5614220A/en not_active Expired - Fee Related
- 1995-02-09 KR KR1019950002367A patent/KR950031048A/en not_active Application Discontinuation
- 1995-02-09 CA CA002142142A patent/CA2142142A1/en not_active Abandoned
- 1995-02-10 EP EP95101828A patent/EP0671167A1/en not_active Withdrawn
- 1995-02-10 CN CN95101372A patent/CN1116926A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX9500885A (en) | 1997-05-31 |
| US5614220A (en) | 1997-03-25 |
| EP0671167A1 (en) | 1995-09-13 |
| KR950031048A (en) | 1995-12-18 |
| CN1116926A (en) | 1996-02-21 |
| JPH07223970A (en) | 1995-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5614220A (en) | Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract | |
| US5725880A (en) | Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract | |
| KR100389602B1 (en) | The lower digestive tract dissolving type skin capsule system | |
| US6251430B1 (en) | Water insoluble polymer based sustained release formulation | |
| US6303144B1 (en) | Preparations with controlled release | |
| US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
| JP3725542B2 (en) | Picosulfate dosage form | |
| JPH09316005A (en) | Pharmaceutical compressed tablet capable of highly increasing volume by contact with body fluid | |
| WO1997047285A1 (en) | Gastric-retentive oral controlled drug delivery system with enhanced retention properties | |
| KR20090065524A (en) | Programmable buoyant delivery technology | |
| JP3633936B2 (en) | Senna dosage form | |
| CA2617051A1 (en) | Ph-controlled pulsatile delivery system, methods for preparation and use thereof | |
| PL207998B1 (en) | Sutained release formulation for venlafaxine hydrochloride | |
| MXPA05004338A (en) | Sustained release compositions containing alfuzosin. | |
| JPH0791184B2 (en) | Controlled release formulation and process for producing the same | |
| US20040146556A1 (en) | Oral extended release tablets and methods of making and using the same | |
| CA2648495C (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
| JPH0798742B2 (en) | Sustained release pharmaceutical composition | |
| JPH04264022A (en) | Oral preparation releasing active component in lower digestive tract | |
| KR20050114921A (en) | Controlled release pharmaceutical compositions | |
| US20050048120A1 (en) | Dosage form comprising self-destructive membrane | |
| US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
| JP2018184360A (en) | Enteric-coated sustained release formulation for oral administration | |
| MXPA96002863A (en) | Pharmaceutical preparation in the form of a liberable coated capsule at the bottom of the digest tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20000209 |